Aim:

To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences.

Methods:

This open-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries.

Results:

The present study enrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase.

Conclusion:

After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.

References

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–6. | Article | PubMed | ChemPort |
2. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607–17. | Article | PubMed | ISI |
3. McCullough A. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies. Curr Urol Rep 2004; 5: 451–9. | Article | PubMed |
4. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257–80. | Article | PubMed | ISI | ChemPort |
5. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–5. | Article | PubMed | ISI |
6. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61: 280–8. | Article | PubMed | ChemPort |
7. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19–30. | Article | PubMed | ISI |
8. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271–5. | Article | PubMed | ChemPort |
9. Ströberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724–37. | Article | PubMed | ISI |
10. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507. | Article | PubMed | ISI | ChemPort |
11. Rosen R, Broderick G, Shabsigh R, Swindle R, Lockhart D, Cameron A. Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. J Sex Med 2005; 2: 461–8. | Article | PubMed | ISI |
12. Dean J, Hackett GI, Gentile V, Farina FP, Rosen RC, Zhao Y, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650–61. | Article | PubMed | ChemPort |
13. Lee SS, Huang ST, Yip WC, Chan LW, Tam PC, Wong THB, et al. Switching from sildenafil (Viagra) to tadalafil (Cialis) in men with erectile dysfunction in Taiwan and Hong Kong: assessment of sexual attempt behavior and psychological and interpersonal relationship scales. Proceedings of the Taiwanese Andrology Association Conference, 2005.
14. Hwang TIS, Yip WC, Gatchalian E, Lei CCM, Cheong NGF, Clarke PJ, et al. Switching from Sildenafil to Tadalafil in Asian Men with Erectile Dysfunction: Assessment of Psychological and Interpersonal Outcomes Associated with Treatment Preference. In: Okuyama A, editor. Proceedings of the 7th Asian Congress of Urology. 2004 Oct 31-Nov 4; Hong Kong, China. Int J Urol 2004; 11(Suppl 1): A22–3.
15. Glina S, Sotomayor M, Gatchalian E, Yaman O, Dyachkova Y, Markey C, et al. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil. J Sex Med 2006; 3: 309–19. | Article | PubMed | ChemPort |
16. Gatchalian E, LVFH Study Group. Switching from Sildenafil (Viagra) to Tadalafil (Cialis) in Filipino Men with Erectile Dysfunction: Assessment of Sexual Attempt Behavior and Psychological and Interpersonal Relationship Scales. In: Proceedings of the Philippines Urological Association Annual Convention; 2004, 2–4.
17. Yaman O, Chlosta P, Kovalev V, Shenfeld O, Pacík D, Breza J, et al. Switching from Sildenafil (Viagra) to Tadalafil (Cialis) in Men with Erectile Dysfunction in Central/East Europe and Eastern Mediterranean Regions: Assessment of Sexual Attempt Behavior and Psychological and Interpersonal Relationship Scales. In: Proceedings of the 7th Congress of the European Society for Sexual Medicine; 2004 Dec 5-8; London, United Kingdom. J Sex Med 2005; 2 (Suppl 1): 65.
18. Cartmill R, Sutherland P, Katelaris P, Mark S, Clarke PJ, Kopernicky V. Switching from Sildenafil (Viagra) to Tadalafil (Cialis) in Men with Erectile Dysfunction in Australia and New Zealand: Assessment of Sexual Attempt Behaviours Relative to the Dosing of Medication. In: Fitzpatrick J, editor. Proceedings of the Urological Society of Australasia Annual Scientific Meeting; 2005 Feb 13-18; Melbourne, Australia. BJU Int 2005; 9 (Suppl 1): 24.
19. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117–20. | PubMed | ISI | ChemPort |
20. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–32. | Article | PubMed | ISI | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.